Adjuvant effect of microencapsulated NOD ligands studied in a human phagocytic cell line

Journal of Applied Biomaterials and Functional Materials

Volumn 10, Issue 3, 2012, Pages 229-236

  Mathew, Simi ^a,b   Roch, Toralf ^a   Frentsch, Marco ^b   Lendlein, Andreas ^a,b   Wischke, Christian ^a,b  

^a INSTITUTE OF MATERIALS RESEARCH   (Germany)

^b Berlin Brandenburg Centre for Regenerative Therapies   (Germany)

Author keywords

Adjuvants; Microparticles; NOD receptor agonists; Particulate vaccines; Poly (rac lactide) co glycolide

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELL CULTURE; CELLS; EMULSIFICATION; IMMUNE SYSTEM; LIGANDS;

ADJUVANT; CELL LINES; GLYCOLIDE; MICRO PARTICLES; NUCLEOTIDE OLIGOMERIZATION DOMAIN RECEPTOR AGONIST; OLIGOMERIZATIONS; PARTICULATE VACCINE; PARTICULATES; POLY(RAC-LACTIDE); POLY[(RAC-LACTIDE)-CO-GLYCOLIDE];

VACCINES;

DIAMINOPIMELIC ACID; ENDOTOXIN; GAMMA GLUTAMYLDIAMINOPIMELIC ACID; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG;

ACUTE MONOCYTIC LEUKEMIA; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENCAPSULATION; EVAPORATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; LEUKEMIA CELL LINE; LIGAND BINDING; MICROEMULSION; PARTICLE SIZE; PHAGOCYTOSIS; SOLVENT EFFECT; SURFACE PROPERTY;

EID: 84874248949     PISSN: None     EISSN: 22808000     Source Type: Journal    
DOI: 10.5301/JABFM.2012.10438     Document Type: Article

References (20)

1. Kwok R. Vaccines: the real issues in vaccine safety. Nature. 2011;473:436-438.
2. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011;473:463-469.
3. Foged C, Hansen J, Agger EM. License to kill: formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci. 2012;45:482-491.
4. Jhunjhunwala S, Raimondi G, Thomson AW, Little SR. Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release. 2009;133:191-197.
5. Schliehe C, Thiry M, Tromsdorf UI, Hentschel J, Weller H, Groettrup M. Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Control Release. 2012;151:278-285.
6. Wischke C, Borchert H-H, Zimmermann J, Siebenbrodt I, Lorenzen DR. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release. 2006;114:359-368.
7. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30:23-32.
8. Benko S, Philpott DJ, Girardin SE. The microbial and danger signals that activate Nod-like receptors. Cytokine. 2008;43:368-373.
9. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6:9-20.
10. Wang C, Muttil P, Lu D, Beltran-Torres AA, GarciaContreras L, Hickey AJ. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. AAPS J. 2009;11:139-147.
11. Puri N, Kou JH, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres: Part I: in vitro characterization. J Control Release. 2000;69:53-67.
12. Wischke C, Mathew S, Roch T, Frentsch M, Lendlein A. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers. J Control Release. 2012; 164: 299-306.
13. Mathew S, Lendlein A, Wischke C. Degradation behavior of porous copolyester microparticles in the light of dynamic changes in their morphology. Macromol Symp. 2011;309-310:123-133.
14. Powell MF, Foster LC, Becker AR, Lee W. Formulation of vaccine adjuvant muramyldipeptides (MDP): Part 2: The thermal reactivity and pH of maximum stability of MDP compounds in aqueous-solution. Pharma Res. 1988;5:528-532.
15. Roch T, Cui J, Kratz K, Lendlein A, Jung F. Immuno compatibility of soft hydrophobic poly (n-butyl acrylate) networks with elastic moduli for regeneration of functional tissues. Clin Hemorheol Microcirc. 2012;50:131-142.
16. Sisson A, Schroeter M, Lendlein A. Polyesters. In: Lendlein A, Sisson A, eds. Handbook of biodegradable polymers: synthesis, characterisation and applications. 1st ed. Weinheim: Wiley-VCH; 2011:1-17.
17. Malyala P, Singh M. Endotoxin limits in formulations for preclinical research. J Pharm Sci. 2008;97:2043-2046.
18. Schliehe C, Redaelli C, Engelhardt S, et al. CD8-dendritic cells and macrophages cross-present poly(D,L-lactateco-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol. 2011;187:2112-2121.
19. Wischke C, Schwendemann SP. Degradable polymeric carriers for parenteral controlled drug delivery. In: Siepmann J, Siegel RA, Rathbone MJ, eds. Fundamentals and applications of controlled release drug delivery. Amsterdam: Harwood Academic; 2011:171-228.
20. Tanzi MC, Bozzini S, Candiani G, et al. Trends in biomedical engineering: focus on smart biomaterials and drug delivery. J Appl Biomater Biomech. 2011;9:87-97.